Sugi Predict

Sugi Predict / Compounds / SCHEMBL4617609

SCHEMBL4617609

SCHEMBL4617609

CC(C)(c1ccccc1)n1nnc(-c2ccccc2)n1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.56
▸ POLB P06746 1/20 0.56
▸ RAB9A P51151 4/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ NPC1 O15118 2/20 0.41
▸ HPGD P15428 1/20 0.41
▸ ATM Q13315 1/20 0.40
▸ MAPK1 P28482 2/20 0.39
▸ TSHR P16473 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6156586 0.85 POLB (0.47) SMN1; SMN2POLBRAB9AL3MBTL1NPC1
SCHEMBL4415031 0.84 SMN1; SMN2 (0.60) SMN1; SMN2POLBRAB9AL3MBTL1NPC1
SCHEMBL4638378 0.82 SMN1; SMN2 (0.51) SMN1; SMN2POLBRAB9AL3MBTL1NPC1
SCHEMBL3393694 0.80 RAB9A (0.47) SMN1; SMN2POLBRAB9AL3MBTL1NPC1
SCHEMBL7772778 0.79 ABCG2 (0.44) SMN1; SMN2POLBRAB9AL3MBTL1NPC1
SCHEMBL4888374 0.77 POLB (0.39) SMN1; SMN2POLBRAB9AL3MBTL1NPC1
SCHEMBL7346198 0.77 NPSR1 (0.50) SMN1; SMN2POLBRAB9AL3MBTL1NPC1
SCHEMBL8783660 0.77 SMN1; SMN2 (0.40) SMN1; SMN2POLBRAB9AL3MBTL1NPC1
SCHEMBL7348668 0.77 POLB (0.40) SMN1; SMN2POLBNPC1ATMALDH1A1
SCHEMBL4414653 0.77 SMN1; SMN2 (0.53) SMN1; SMN2POLBRAB9AL3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103864706-A Preparation method for 2-isopropylphenyl-5-phenyltetrazole ANHUI LANGXI LIANKE IND CO LTD 2014-06-18 — — CN claimed
CN-103554048-A Preparation method of 2-isopropylphenyl-5-phenyl tetrazolium ANHUI LANGXI LIANKE IND CO LTD 2014-02-05 — — CN claimed
EP-0760815-A1 PROCESSES FOR PREPARING 1-BUTYL-2-[2'-(2H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-1H-INDOLE-3-CARBOXYLIC ACID SYNTEX (U.S.A.) INC. (US) 1997-03-12 — — EP claimed
WO-1995032962-A1 PROCESSES FOR PREPARING 1-BUTYL-2-[2'-(2H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-1H-INDOLE-3-CARBOXYLIC ACID SYNTEX (U.S.A.) INC. (US) 1995-12-07 — — WO claimed
US-5412102-A Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid SYNTEX (U.S.A.) INC. (US) 1995-05-02 — — US claimed
EP-4707391-A1 NUCLEIC ACID COMPOUNDS FOR ZPI INHIBITION e-therapeutics PLC (GB) 2026-03-11 — — EP disclosed
CN-103864706-A Preparation method for 2-isopropylphenyl-5-phenyltetrazole ANHUI LANGXI LIANKE IND CO LTD 2014-06-18 — — CN disclosed
CN-103554048-A Preparation method of 2-isopropylphenyl-5-phenyl tetrazolium ANHUI LANGXI LIANKE IND CO LTD 2014-02-05 — — CN disclosed
US-7385062-B2 Process for the preparation of phenyltetrazole derivatives DIPHARMA S.P.A. (IT) 2008-06-10 — — US disclosed
EP-1891053-A1 METHOD FOR OBTAINING BENZIMIDAZOLE DERIVATIVES AND INTERMEDIATES THEREOF Quimica Sintetica, S.A. (ES) 2008-02-27 — — EP disclosed
EP-1660463-B1 A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES DIPHARMA FRANCIS SRL (IT) 2007-12-05 — — EP disclosed
WO-2006134078-A1 METHOD FOR OBTAINING BENZIMIDAZOLE DERIVATIVES AND INTERMEDIATES THEREOF QUIMICA SINTETICA, S.A. (ES) 2006-12-21 — — WO disclosed
US-20060183916-A1 Process for the preparation of phenyltetrazole derivatives DIPHARMA S.P.A. (IT) 2006-08-17 — — US disclosed
EP-1660463-A1 A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES Dipharma S.p.A. (IT) 2006-05-31 — — EP disclosed
WO-2005014560-A1 A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES DIPHARMA S.P.A. (IT) 2005-02-17 — — WO disclosed
EP-0760815-A1 PROCESSES FOR PREPARING 1-BUTYL-2-[2'-(2H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-1H-INDOLE-3-CARBOXYLIC ACID SYNTEX (U.S.A.) INC. (US) 1997-03-12 — — EP disclosed
US-5527918-A Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid SYNTEX (U.S.A.) INC. (US) 1996-06-18 — — US disclosed
WO-1995032962-A1 PROCESSES FOR PREPARING 1-BUTYL-2-[2'-(2H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-1H-INDOLE-3-CARBOXYLIC ACID SYNTEX (U.S.A.) INC. (US) 1995-12-07 — — WO disclosed
US-5446121-A Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid SYNTEX (U.S.A.) INC. (US) 1995-08-29 — — US disclosed
US-5412102-A Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid SYNTEX (U.S.A.) INC. (US) 1995-05-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183916-A1 Process for the preparation of phenyltetrazole derivatives AGTR2, ACE, AGTR1 SMN1; SMN2 4704/4885POLB 494/4885RAB9A 2843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.